| (Values in U.S. Thousands) | Oct, 2025 | Oct, 2024 | Oct, 2023 | Oct, 2022 | Oct, 2021 |
| Sales | 782 | 702 | 868 | 1,300 | 981 |
| Sales Growth | +11.40% | -19.11% | -33.22% | +32.49% | +36.57% |
| Net Income | -333 | -456 | -547 | -150 | -604 |
| Net Income Growth | +27.00% | +16.60% | -264.69% | +75.17% | +29.19% |
Eastwood Bio Medical Canada Inc (EBM.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
Fiscal Year End Date: 10/31